Home

Johnson & Johnson (JNJ)

191.08
+1.39 (0.73%)
NYSE · Last Trade: Oct 9th, 4:41 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close189.69
Open190.00
Bid190.89
Ask191.00
Day's Range189.73 - 192.10
52 Week Range140.68 - 190.21
Volume7,397,168
Market Cap502.29B
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield5.200 (2.72%)
1 Month Average Volume8,575,009

Chart

About Johnson & Johnson (JNJ)

Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More

News & Press Releases

Johnson & Johnson to Participate in the UBS Global Healthcare Conference
Johnson & Johnson (NYSE: JNJ) will present at the UBS Global Healthcare Conference on Tuesday, November 11th, 2025. Management will participate in a Fireside Chat at 11:00 a.m. Eastern Time.
By Johnson & Johnson · Via Business Wire · October 9, 2025
What Analysts Are Saying About Johnson & Johnson Stockbenzinga.com
Via Benzinga · October 9, 2025
Top US Bankers Sound Alarm: Brace for Potential Stock Market Decline
In a series of recent and increasingly pointed warnings, some of America's most influential financial leaders are cautioning investors to prepare for a significant stock market downturn within the coming years. This chorus of cautionary outlooks, spearheaded by figures such as Jamie Dimon of JPMorgan Chase, Larry Fink of BlackRock,
Via MarketMinute · October 9, 2025
Investors Brace for Pullback as Short-Bias ETF Inflows Signal Growing Bearishness
A significant surge in capital flowing into short-bias Exchange-Traded Funds (ETFs) has sent a clear signal through the financial markets: investor sentiment is shifting towards caution and a potential stock market pullback. This notable trend, particularly pronounced in recent weeks, suggests that a growing number of investors are actively positioning
Via MarketMinute · October 9, 2025
Market Giants Retreat: S&P 500 and Nasdaq Pull Back from Record Highs Amidst Economic Headwinds
The relentless ascent of the U.S. stock market has hit a significant speed bump, as both the S&P 500 and Nasdaq Composite have retreated from their recent record highs. This pullback, occurring after weeks of robust gains, signals a period of reassessment for investors grappling with a confluence
Via MarketMinute · October 9, 2025
The Looming Spectre: What Could Puncture the Stock Market's AI-Driven Bubble?
As October 2025 unfolds, a palpable tension hangs over global financial markets. Despite record highs in major indices like the Nasdaq 100 (NASDAQ: NDX) and the FTSE 100 (LSE: UKX), a growing chorus of analysts and economists are sounding the alarm, warning that the stock market is exhibiting classic signs
Via MarketMinute · October 9, 2025
Federal Reserve Navigates Rate Cuts Amidst Lingering Inflationary Shadows
The Federal Reserve has embarked on a delicate balancing act, initiating interest rate cuts in 2025 to bolster a softening labor market while grappling with persistent inflation concerns among some of its most influential officials. As of October 8, 2025, financial markets are closely scrutinizing every statement and data point,
Via MarketMinute · October 8, 2025
FDA Expands Johnson & Johnson Ulcerative Colitis Drug Approval To Pediatric Patientsbenzinga.com
FDA approves Johnson & Johnson's Simponi for children with moderate to severe ulcerative colitis, supported by positive Phase 3 trial results.
Via Benzinga · October 8, 2025
These Were the 5 Worst-Performing Stocks in the S&P 500 in September 2025 -- and One's Decline Can Be Tied to President Trumpfool.com
One of these stocks lost about a quarter of its value in a single month.
Via The Motley Fool · October 8, 2025
Why AbbVie and Johnson & Johnson Could Outperform Pfizermarketbeat.com
Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential
Via MarketBeat · October 8, 2025
Worried About a Recession? 2 Stocks to Buy Now to Prepare Your Portfoliofool.com
These two market leaders have increased their dividends for a combined 115 years.
Via The Motley Fool · October 7, 2025
Healthcare Sector Defies Broader Market Swings, Leads S&P 500 Momentum on October 7, 2025
On a day where the broader S&P 500 and Nasdaq Composite indices soared to new all-time record highs, the S&P 500 Healthcare sector presented a compelling, albeit nuanced, narrative of market leadership and resilience. While the overall market sentiment exuded robust optimism, the healthcare sector itself showcased a
Via MarketMinute · October 7, 2025
Congresswoman Violates STOCK Act With Late Trade Disclosures: Purchases Include Bitcoin ETFbenzinga.com
As legislation in Congress heats up to ban elected officials from buying and selling stocks, several members have violated the STOCK Act in 2025, failing to disclose their transactions in a timely fashion.
Via Benzinga · October 7, 2025
Johnson & Johnson Reportedly Ordered To Pay $966M To Family Of Woman Who Died Of Rare Cancer Allegedly Associated With Its Talcstocktwits.com
According to a Reuters report, a Los Angeles Jury has ordered the company to pay $16 million in compensatory damages and $950 million in punitive damages.
Via Stocktwits · October 7, 2025
Top S&P500 movers in Tuesday's pre-market sessionchartmill.com
The US market session of Tuesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.
Via Chartmill · October 7, 2025
1 Reason I'm Watching Intuitive Surgical Stock in 2026fool.com
The surgical robotics pioneer could cement its leading position for years to come.
Via The Motley Fool · October 7, 2025
Johnson & Johnson to Participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Johnson & Johnson (NYSE: JNJ) will present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Tuesday, November 11th, 2025. Management will participate in a Fireside Chat at 10:30 a.m. Eastern Time.
By Johnson & Johnson · Via Business Wire · October 6, 2025
Options Corner: Despite Political Woes, Kenvue Can Still Make Tylenol Great Againbenzinga.com
While Kenvue's Tylenol has attracted intense political pressure, speculators are determined to make KVUE stock great again.
Via Benzinga · October 6, 2025
U.S. Labor Market Stalls: Moody's Reports 'Essentially No Job Growth' Amidst Government Shutdown, Raising Recession Fears
Washington D.C., October 6, 2025 – The American labor market appears to have hit a significant speed bump, with Moody's Analytics reporting "essentially no job growth" for the U.S. in September 2025. This concerning assessment comes at a critical juncture for the economy, compounded by an ongoing federal government
Via MarketMinute · October 6, 2025
Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giantsmarketbeat.com
Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.
Via MarketBeat · October 6, 2025
Navigating the Storm: Essential Strategies to Avoid 'Bag Holder' Status in Volatile Markets
The financial markets, as of October 4, 2025, continue to be characterized by a significant degree of volatility, presenting both opportunities and perilous traps for investors. In such an environment, one of the most dreaded outcomes is becoming a "bag holder" – an investor left clinging to a security that has
Via MarketMinute · October 4, 2025
Market Defies D.C. Gridlock: S&P 500 and Dow Jones Soar to Record Highs Amidst Government Shutdown
The U.S. financial markets are currently presenting a perplexing paradox. As of October 4, 2025, both the S&P 500 and Dow Jones Industrial Average (DJIA) have surged to unprecedented record highs, exhibiting remarkable resilience. This bullish momentum, however, unfolds against a backdrop of significant political turmoil: the federal
Via MarketMinute · October 4, 2025
US Government Shutdown Casts Global Shadow: Economic Data Delays Fuel Investor Uncertainty
The United States government is currently in the throes of a shutdown, commencing at 12:01 a.m. EDT on October 1, 2025, after a congressional impasse prevented the passage of appropriations legislation for the 2026 fiscal year. This fiscal stalemate has immediately plunged global financial markets into a state
Via MarketMinute · October 3, 2025
Healthcare Stands Strong: A Pillar in the S&P 500 Amidst Tech Sector Retreat
As the S&P 500 navigates a dynamic market on October 3, 2025, the Healthcare sector has emerged as a steadfast performer, demonstrating remarkable resilience and contributing significantly to the overall market's strength. This stability comes at a crucial time, as the technology sector experiences a notable pullback, leading investors
Via MarketMinute · October 3, 2025
Data Blackout: Government Shutdown Leaves Fed Flying Blind Amidst Economic Crossroads
The U.S. economy finds itself at a critical juncture, navigating persistent inflation and a cooling labor market, while simultaneously grappling with the immediate and profound implications of an ongoing government shutdown. As of October 3, 2025, the federal government remains unfunded, triggering a widespread data blackout that has delayed
Via MarketMinute · October 3, 2025